The Impact of Delayed Chemotherapy on Its Completion and Survival Outcomes in Stage II Colon Cancer Patients
Open Access
- 19 September 2014
- journal article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (9), e107993
- https://doi.org/10.1371/journal.pone.0107993
Abstract
Delayed chemotherapy is associated with inferior survival in stage III colon and stage II/III rectal cancer patients, but similar studies have not been performed in stage II colon cancer patients. We investigate the association between delayed and incomplete chemotherapy, and the association of delayed chemotherapy with survival in stage II colon cancer patients. Patients (age ≥66) diagnosed as stage II colon cancer and received chemotherapy from 1992 to 2005 were identified from the linked SEER–Medicare database. The association between delayed and incomplete chemotherapy was assessed using unconditional and conditional logistic regressions. Survival outcomes were assessed using stratified Cox regression based on propensity score matched samples. 4,209 stage II colon cancer patients were included, of whom 73.0% had chemotherapy initiated timely (≤2 months after surgery), 14.7% had chemotherapy initiated with moderate delay (2–3 months), and 12.3% had delayed chemotherapy (≥3 months). Delayed chemotherapy was associated with not completing chemotherapy (adjusted odds ratio (OR): 1.33 (95% confidence interval: 1.11, 1.59) for moderately delayed group, adjusted OR: 2.60 (2.09, 3.24) for delayed group). Delayed chemotherapy was associated with worse survival outcomes (hazard ratio (HR): 1.75 (1.29, 2.37) for overall survival; HR: 4.23 (2.19, 8.20) for cancer-specific survival). Although the benefit of chemotherapy is unclear in stage II colon cancer patients, delay in initiation of chemotherapy is associated with an incomplete chemotherapy course and poorer survival, especially cancer-specific survival. Causal inference in the association between delayed initiation of chemotherapy and inferior survival requires further investigation.This publication has 33 references indexed in Scilit:
- Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic FeaturesJournal of Clinical Oncology, 2011
- Early Discontinuation but Not the Timing of Adjuvant Therapy Affects Survival of Patients With High-Risk Colorectal Cancer: A Population-Based StudyDiseases of the Colon & Rectum, 2010
- Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysisEuropean Journal of Cancer, 2010
- Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general populationCancer, 2008
- Completion of Therapy by Medicare Patients With Stage III Colon CancerJNCI Journal of the National Cancer Institute, 2006
- Completion Rates of Adjuvant Chemotherapy for Colon Cancer: A Historical PerspectiveJNCI Journal of the National Cancer Institute, 2006
- ERRATUMActa Oncologica, 2006
- Dose–response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancerEuropean Journal of Cancer, 1998
- Explanatory models for cancer among African-American women at two Atlanta neighborhood health centers: The implications for a cancer screening programSocial Science & Medicine (1982), 1994
- Surgical adjuvant chemotherapy.Results with one short course with cyclophosphamide after mastectomy for breast cancerCancer, 1978